Overview

Study of Testosterone vs Placebo in Testicular Cancer Survivors

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The overall purpose of the study is to evaluate the effect of 12 months testosterone replacement therapy in testicular cancer survivors with mild Leydig Cell Insufficiency in order to reduce the risk of cardiovascular disease. The primary study objective is to evaluate changes in insulin sensitivity. The secondary study objective is to evaluate changes in the prevalence of metabolic syndrome, body composition, systemic inflammation and symptoms of testosterone deficiency.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mikkel Bandak
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate